Perspective Therapeutics Names Juan Graham as Finance Chief

Dow Jones

01-06

By Denny Jacob

Perspective Therapeutics named Juan Graham as chief financial officer.

The Seattle-based radiopharmaceutical company on Monday said Jonathan Hunt will no longer serve as CFO in connection with the change but will continue to serve as its chief accounting officer.

Graham previously served as CFO of FibroGen, an emerging biopharmaceutical company.

Perspective will pay Graham an annual base salary of $500,000, and he will be eligible for an annual bonus based on a target bonus opportunity of 40% of the salary. Graham will also receive a one-time signing bonus of $80,000 and an equity grant of options to purchase 400,000 shares of the company's common stock, according to a securities filing.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

January 06, 2025 08:26 ET (13:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2501281231"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501281231\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2501281231?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-06 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501281231","market":"other","top_or_hot":-1,"title":"Perspective Therapeutics Names Juan Graham as Finance Chief","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CATX\">Perspective Therapeutics</a> named Juan Graham as chief financial officer. \n</p>\n<p>\n  The Seattle-based radiopharmaceutical company on Monday said Jonathan Hunt will no longer serve as CFO in connection with the change but will continue to serve as its chief accounting officer. \n</p>\n<p>\n  Graham previously served as CFO of FibroGen, an emerging biopharmaceutical company. \n</p>\n<p>\n  Perspective will pay Graham an annual base salary of $500,000, and he will be eligible for an annual bonus based on a target bonus opportunity of 40% of the salary. Graham will also receive a one-time signing bonus of $80,000 and an equity grant of options to purchase 400,000 shares of the company's common stock, according to a securities filing. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2025 08:26 ET (13:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Perspective Therapeutics Names Juan Graham as Finance Chief</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPerspective Therapeutics Names Juan Graham as Finance Chief\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-06 21:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CATX\">Perspective Therapeutics</a> named Juan Graham as chief financial officer. \n</p>\n<p>\n  The Seattle-based radiopharmaceutical company on Monday said Jonathan Hunt will no longer serve as CFO in connection with the change but will continue to serve as its chief accounting officer. \n</p>\n<p>\n  Graham previously served as CFO of FibroGen, an emerging biopharmaceutical company. \n</p>\n<p>\n  Perspective will pay Graham an annual base salary of $500,000, and he will be eligible for an annual bonus based on a target bonus opportunity of 40% of the salary. Graham will also receive a one-time signing bonus of $80,000 and an equity grant of options to purchase 400,000 shares of the company's common stock, according to a securities filing. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2025 08:26 ET (13:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CATX","symbol_name":"Perspective Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2501281231","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501281231","pubTimestamp":1736169960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Perspective Therapeutics named Juan Graham as chief financial officer.Graham previously served as CFO of FibroGen, an emerging biopharmaceutical company.Perspective will pay Graham an annual base salary of $500,000, and he will be eligible for an annual bonus based on a target bonus opportunity of 40% of the salary. Graham will also receive a one-time signing bonus of $80,000 and an equity grant of options to purchase 400,000 shares of the company's common stock, according to a securities filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CATX":"Perspective Therapeutics","BK4139":"生物科技"},"translate_title":"Perspective Therapeutics任命Juan Graham为财务主管","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CATX":1},"content_text":"By Denny Jacob \n\n\n \n\n\nPerspective Therapeutics named Juan Graham as chief financial officer. \n\n\n  The Seattle-based radiopharmaceutical company on Monday said Jonathan Hunt will no longer serve as CFO in connection with the change but will continue to serve as its chief accounting officer. \n\n\n  Graham previously served as CFO of FibroGen, an emerging biopharmaceutical company. \n\n\n  Perspective will pay Graham an annual base salary of $500,000, and he will be eligible for an annual bonus based on a target bonus opportunity of 40% of the salary. Graham will also receive a one-time signing bonus of $80,000 and an equity grant of options to purchase 400,000 shares of the company's common stock, according to a securities filing. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2025 08:26 ET (13:26 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}